265 related articles for article (PubMed ID: 7908410)
21. p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients.
Bottini A; Berruti A; Bersiga A; Brizzi MP; Brunelli A; Gorzegno G; DiMarco B; Aguggini S; Bolsi G; Cirillo F; Filippini L; Betri E; Bertoli G; Alquati P; Dogliotti L
Clin Cancer Res; 2000 Jul; 6(7):2751-8. PubMed ID: 10914720
[TBL] [Abstract][Full Text] [Related]
22. Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer.
Tallman MS; Gray R; Robert NJ; LeMaistre CF; Osborne CK; Vaughan WP; Gradishar WJ; Pisansky TM; Fetting J; Paietta E; Lazarus HM
N Engl J Med; 2003 Jul; 349(1):17-26. PubMed ID: 12840088
[TBL] [Abstract][Full Text] [Related]
23. p53 as a specific prognostic factor in triple-negative breast cancer.
Chae BJ; Bae JS; Lee A; Park WC; Seo YJ; Song BJ; Kim JS; Jung SS
Jpn J Clin Oncol; 2009 Apr; 39(4):217-24. PubMed ID: 19304743
[TBL] [Abstract][Full Text] [Related]
24. Sequenced compared with simultaneous anthracycline and cyclophosphamide in high-risk stage I and II breast cancer: final analysis from INT-0137 (S9313).
Linden HM; Haskell CM; Green SJ; Osborne CK; Sledge GW; Shapiro CL; Ingle JN; Lew D; Hutchins LF; Livingston RB; Martino S
J Clin Oncol; 2007 Feb; 25(6):656-61. PubMed ID: 17308269
[TBL] [Abstract][Full Text] [Related]
25. Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience.
Muss HB; Berry DA; Cirrincione C; Budman DR; Henderson IC; Citron ML; Norton L; Winer EP; Hudis CA;
J Clin Oncol; 2007 Aug; 25(24):3699-704. PubMed ID: 17704418
[TBL] [Abstract][Full Text] [Related]
26. Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease.
Press MF; Pike MC; Chazin VR; Hung G; Udove JA; Markowicz M; Danyluk J; Godolphin W; Sliwkowski M; Akita R
Cancer Res; 1993 Oct; 53(20):4960-70. PubMed ID: 8104689
[TBL] [Abstract][Full Text] [Related]
27. BCIRG 001 molecular analysis: prognostic factors in node-positive breast cancer patients receiving adjuvant chemotherapy.
Dumontet C; Krajewska M; Treilleux I; Mackey JR; Martin M; Rupin M; Lafanechère L; Reed JC
Clin Cancer Res; 2010 Aug; 16(15):3988-97. PubMed ID: 20576719
[TBL] [Abstract][Full Text] [Related]
28. erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer.
Thor AD; Berry DA; Budman DR; Muss HB; Kute T; Henderson IC; Barcos M; Cirrincione C; Edgerton S; Allred C; Norton L; Liu ET
J Natl Cancer Inst; 1998 Sep; 90(18):1346-60. PubMed ID: 9747866
[TBL] [Abstract][Full Text] [Related]
29. p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer.
Clahsen PC; van de Velde CJ; Duval C; Pallud C; Mandard AM; Delobelle-Deroide A; van den Broek L; Sahmoud TM; van de Vijver MJ
J Clin Oncol; 1998 Feb; 16(2):470-9. PubMed ID: 9469330
[TBL] [Abstract][Full Text] [Related]
30. Influence of activation state of ErbB-2 (HER-2) on response to adjuvant cyclophosphamide, doxorubicin, and fluorouracil for stage II, node-positive breast cancer: study 8541 from the Cancer and Leukemia Group B.
DiGiovanna MP; Stern DF; Edgerton S; Broadwater G; Dressler LG; Budman DR; Henderson IC; Norton L; Liu ET; Muss HB; Berry DA; Hayes DF; Thor AD
J Clin Oncol; 2008 May; 26(14):2364-72. PubMed ID: 18390970
[TBL] [Abstract][Full Text] [Related]
31. Understanding adjuvant chemotherapy for breast cancer.
Goldhirsch A; Gelber RD
N Engl J Med; 1994 May; 330(18):1308-9. PubMed ID: 7908411
[No Abstract] [Full Text] [Related]
32. Cyclophosphamide dose intensification may circumvent anthracycline resistance of p53 mutant breast cancers.
Lehmann-Che J; André F; Desmedt C; Mazouni C; Giacchetti S; Turpin E; Espié M; Plassa LF; Marty M; Bertheau P; Sotiriou C; Piccart M; Symmans WF; Pusztai L; de Thé H
Oncologist; 2010; 15(3):246-52. PubMed ID: 20228131
[TBL] [Abstract][Full Text] [Related]
33. [Correlation of metastasis-free survival in patients with breast cancer and changes in the direction of expression of multidrug resistance genes during neoadjuvant chemotherapy].
Litviakov NV; Garbukov EIu; Slonimskaia EM; Tsyganov MM; Denisov EV; Vtorushin SV; Khristenko KIu; Zav'ialova MV; Cherdyntseva NV
Vopr Onkol; 2013; 59(3):334-40. PubMed ID: 23909034
[TBL] [Abstract][Full Text] [Related]
34. HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer.
Berry DA; Muss HB; Thor AD; Dressler L; Liu ET; Broadwater G; Budman DR; Henderson IC; Barcos M; Hayes D; Norton L
J Clin Oncol; 2000 Oct; 18(20):3471-9. PubMed ID: 11032587
[TBL] [Abstract][Full Text] [Related]
35. Topoisomerase II-α as a predictive factor of response to therapy with anthracyclines in locally advanced breast cancer.
Gómez HL; Pinto JA; Olivera M; Vidaurre T; Doimi FD; Vigil CE; Velarde RG; Abugattas JE; Alarcón E; Vallejos CS
Breast; 2011 Feb; 20(1):39-45. PubMed ID: 20705464
[TBL] [Abstract][Full Text] [Related]
36. SERPINA6, BEX1, AGTR1, SLC26A3, and LAPTM4B are markers of resistance to neoadjuvant chemotherapy in HER2-negative breast cancer.
de Ronde JJ; Lips EH; Mulder L; Vincent AD; Wesseling J; Nieuwland M; Kerkhoven R; Vrancken Peeters MJ; Sonke GS; Rodenhuis S; Wessels LF
Breast Cancer Res Treat; 2013 Jan; 137(1):213-23. PubMed ID: 23203637
[TBL] [Abstract][Full Text] [Related]
37. [Adjuvant chemotherapy in older women with breast cancer. CALGB Study (The Cancer and Leukemia Group B Study)].
Mallmann P; Nitschmann S
Internist (Berl); 2010 Jul; 51(7):923-4. PubMed ID: 20544172
[No Abstract] [Full Text] [Related]
38. Tumor STAT3 tyrosine phosphorylation status, as a predictor of benefit from adjuvant chemotherapy for breast cancer.
Sonnenblick A; Uziely B; Nechushtan H; Kadouri L; Galun E; Axelrod JH; Katz D; Daum H; Hamburger T; Maly B; Allweis TM; Peretz T
Breast Cancer Res Treat; 2013 Apr; 138(2):407-13. PubMed ID: 23446809
[TBL] [Abstract][Full Text] [Related]
39. E2F1 expression is related with the poor survival of lymph node-positive breast cancer patients treated with fluorouracil, doxorubicin and cyclophosphamide.
Han S; Park K; Bae BN; Kim KH; Kim HJ; Kim YD; Kim HY
Breast Cancer Res Treat; 2003 Nov; 82(1):11-6. PubMed ID: 14672398
[TBL] [Abstract][Full Text] [Related]
40. Expression of the high-affinity fluoropyrimidine-preferring nucleoside transporter hCNT1 correlates with decreased disease-free survival in breast cancer.
Gloeckner-Hofmann K; Guillén-Gómez E; Schmidtgen C; Porstmann R; Ziegler R; Stoss O; Casado FJ; Rüschoff J; Pastor-Anglada M
Oncology; 2006; 70(3):238-44. PubMed ID: 16837820
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
